Trial Outcomes & Findings for The Effects of Rimonabant, on Weight and Metabolic Risk Factors (NCT NCT00547118)
NCT ID: NCT00547118
Last Updated: 2019-11-04
Results Overview
The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from "1=Not Present" to "7=Very Severe". Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.
TERMINATED
PHASE2
17 participants
Baseline (Week 0) and end of study (Week 16)
2019-11-04
Participant Flow
18 participants signed consent for the study. 1 participant was withdrawn prior to randomization, 2 participants (one from each group) withdrawn after randomization but prior to drug initiation. n=15 participants included in data analysis for aims 1, 2, 8, 9, 10, and n=14 analyzed for aims 3-7 due withdrawal prior to EOS neruopsych testing.
Participant milestones
| Measure |
Rimonabant
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
|
Placebo
Placebo
Placebo: Placebo
|
|---|---|---|
|
Overall Study
STARTED
|
8
|
9
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
8
|
9
|
Reasons for withdrawal
| Measure |
Rimonabant
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
|
Placebo
Placebo
Placebo: Placebo
|
|---|---|---|
|
Overall Study
Did not qualify prior to starting drug
|
1
|
1
|
|
Overall Study
Study suspended
|
7
|
8
|
Baseline Characteristics
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
Baseline characteristics by cohort
| Measure |
Rimonabant
n=7 Participants
Rimonabant
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo
Placebo: Placebo
|
Total
n=15 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
7 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Continuous
|
45.9 Years
STANDARD_DEVIATION 6.9 • n=99 Participants
|
42.4 Years
STANDARD_DEVIATION 13.3 • n=107 Participants
|
45.7 Years
STANDARD_DEVIATION 8.4 • n=206 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
7 participants
n=99 Participants
|
8 participants
n=107 Participants
|
15 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from "1=Not Present" to "7=Very Severe". Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Brief Psychiatric Rating Scale (BPRS) Total Score
Week 0
|
33.5 units on a scale
Standard Deviation 7.5
|
34.5 units on a scale
Standard Deviation 4.6
|
|
Brief Psychiatric Rating Scale (BPRS) Total Score
Week 16
|
32.8 units on a scale
Standard Deviation 3.9
|
33.6 units on a scale
Standard Deviation 6.2
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from "1=Not Present" to "7=Very Severe". The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Brief Psychiatric Rating Scale (BPRS) Psychosis Score
Week 0
|
9.4 units on a scale
Standard Deviation 4.3
|
11.4 units on a scale
Standard Deviation 3.4
|
|
Brief Psychiatric Rating Scale (BPRS) Psychosis Score
Week 16
|
7.6 units on a scale
Standard Deviation 3.0
|
8.6 units on a scale
Standard Deviation 3.4
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).
The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 0
|
85.0 units on a scale
Standard Deviation 19.8
|
78.3 units on a scale
Standard Deviation 10.2
|
|
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Week 16
|
83.0 units on a scale
Standard Deviation 11.8
|
84.3 units on a scale
Standard Deviation 12.6
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).
The Iowa Gambling Task (IGT) is a computer-administered cognitive test that assesses risk preferences by simulating real-life decision making using uncertainty, rewards, and penalties. In the task, players are given four decks of cards and an endowment of fake money (e.g., $2000). Players are instructed to select cards one at a time and try to lose the least amount of money and win the most. The outcome measure was the number of rewarded minus punished card choices. Task has a maximum of 100 trials. The net score is the difference between the number of choices from advantageous decks verses disadvantageous decks. Higher scores are better and can range from -50 to +50.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
The Iowa Gambling Task (IGT)
Week 0
|
5.1 units on a scale
Standard Deviation 19.8
|
1.3 units on a scale
Standard Deviation 22.7
|
|
The Iowa Gambling Task (IGT)
Week 16
|
-0.3 units on a scale
Standard Deviation 25.2
|
-9.0 units on a scale
Standard Deviation 29.7
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).
The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
N-Back Neurocognitive Task: 0-back Condition
Week 0
|
3.8 units on a scale
Standard Deviation 0.5
|
3.6 units on a scale
Standard Deviation 0.6
|
|
N-Back Neurocognitive Task: 0-back Condition
Week 16
|
3.9 units on a scale
Standard Deviation 0.6
|
3.6 units on a scale
Standard Deviation 0.4
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).
The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
N-Back Neurocognitive Task: 1-back Condition
Week 0
|
3.2 units on a scale
Standard Deviation 0.8
|
3.2 units on a scale
Standard Deviation 0.6
|
|
N-Back Neurocognitive Task: 1-back Condition
Week 16
|
3.3 units on a scale
Standard Deviation 0.7
|
2.8 units on a scale
Standard Deviation 0.2
|
PRIMARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: 14 (R n=7, P n=7) completed baseline and End Of Study (EOS), 16 wk. Neurocognitive assessments (i.e. RBANS); 1 P pt. failed to complete the other EOS neurocognitive tests. 5 R pts. and 4 P pts. completed the 16-wk. treatment phase; the other 2 R pts. completed 11 and 13 wks. and 3 P pts. completed 13 (n=2) and 15 wks. (n=1).
The N-Back task is a sequential letter working memory task. D-prime was used to measure accuracy on the 0-back, 1-back, and 2-back conditions. D-prime scores range from 0 to 8.6. Higher scores are better. As memory load increases from 0 to 1, from 1 to 2, D-prime scores are expected to be lower.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=7 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
N-Back Neurocognitive Task: 2-back Condition
Week 0
|
1.5 units on a scale
Standard Deviation 0.6
|
1.6 units on a scale
Standard Deviation 0.6
|
|
N-Back Neurocognitive Task: 2-back Condition
Week 16
|
1.5 units on a scale
Standard Deviation 0.4
|
1.6 units on a scale
Standard Deviation 0.4
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Schedule for Assessment of Negative Symptoms (SANS) Total Score
Week 0
|
28.7 units on a scale
Standard Deviation 10.9
|
26.7 units on a scale
Standard Deviation 15.5
|
|
Schedule for Assessment of Negative Symptoms (SANS) Total Score
Week 16
|
33.2 units on a scale
Standard Deviation 11.6
|
32.4 units on a scale
Standard Deviation 15.8
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
SANS Global Anhedonia score. Scores can range from 0-5, with higher scores indicating more severe anhedonia.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Schedule for Assessment of Negative Symptoms (SANS) - Anhedonia
Week 0
|
1.9 units on a scale
Standard Deviation 1.0
|
1.6 units on a scale
Standard Deviation 0.9
|
|
Schedule for Assessment of Negative Symptoms (SANS) - Anhedonia
Week 16
|
1.9 units on a scale
Standard Deviation 1.0
|
1.9 units on a scale
Standard Deviation 1.1
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
SANS Global Rating of Affective Flattening. Scores can range from 0-5, with higher scores indicating more severe blunted affect.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Schedule for Assessment of Negative Symptoms (SANS) - Blunted Affect
Week 0
|
1.3 units on a scale
Standard Deviation 0.9
|
1.1 units on a scale
Standard Deviation 1.0
|
|
Schedule for Assessment of Negative Symptoms (SANS) - Blunted Affect
Week 16
|
1.8 units on a scale
Standard Deviation 0.9
|
1.2 units on a scale
Standard Deviation 1.0
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
SANS Global Rating of Alogia. Scores can range from 0-5, with higher scores indicating more severe alogia.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Schedule for Assessment of Negative Symptoms (SANS) - Alogia
Week 0
|
0.5 units on a scale
Standard Deviation 0.5
|
0.9 units on a scale
Standard Deviation 1.4
|
|
Schedule for Assessment of Negative Symptoms (SANS) - Alogia
Week 16
|
0.9 units on a scale
Standard Deviation 1.1
|
1.4 units on a scale
Standard Deviation 1.3
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
SANS Avolition score. Scores can range from 0-5, with higher scores indicating more severe avolition.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Schedule for Assessment of Negative Symptoms (SANS) - Avolition
Week 0
|
2.6 units on a scale
Standard Deviation 1.1
|
2.4 units on a scale
Standard Deviation 1.1
|
|
Schedule for Assessment of Negative Symptoms (SANS) - Avolition
Week 16
|
2.6 units on a scale
Standard Deviation 1.2
|
3.0 units on a scale
Standard Deviation 1.2
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
The global improvement score can range from 1-7, with higher scores indicating worse total improvement clinically.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Clinical Global Impression (CGI)
Week 16
|
4.2 units on a scale
Standard Deviation 0.4
|
4.0 units on a scale
Standard Deviation 1.0
|
|
Clinical Global Impression (CGI)
Week 0
|
4.2 units on a scale
Standard Deviation 0.4
|
4.2 units on a scale
Standard Deviation 0.7
|
SECONDARY outcome
Timeframe: Baseline (Week 0) and end of study (Week 16)Population: Because of early study termination, 2 participants on rimonabant and 3 on placebo were withdrawn before completion.
The CDS total score is the addition of scores from items 1-9. Each item's scores range on a scale of "0=Absent" to "3=Severe". The total score range is from 0-27. Higher total scores indicate a more severe depression rating.
Outcome measures
| Measure |
Rimonabant
n=7 Participants
One 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=8 Participants
Placebo tablet given 1 time per day for 112 days
|
|---|---|---|
|
Calgary Depression Scale (CDS) Total Score
Week 0
|
3.0 units on a scale
Standard Deviation 2.2
|
3.0 units on a scale
Standard Deviation 2.4
|
|
Calgary Depression Scale (CDS) Total Score
Week 16
|
2.0 units on a scale
Standard Deviation 2.5
|
2.0 units on a scale
Standard Deviation 2.7
|
Adverse Events
Rimonabant
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Rimonabant
n=8 participants at risk
Rimonabant: Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
|
Placebo
n=9 participants at risk
Placebo
Placebo: Placebo
|
|---|---|---|
|
General disorders
Headache
|
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
55.6%
5/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Renal and urinary disorders
Enuresis
|
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Metabolism and nutrition disorders
Anorexia
|
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
33.3%
3/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Respiratory, thoracic and mediastinal disorders
Sedation
|
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Gastrointestinal disorders
Abdominal pain
|
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Metabolism and nutrition disorders
weight loss
|
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
44.4%
4/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
General disorders
malaise
|
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
33.3%
3/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Ear and labyrinth disorders
tinnitus
|
37.5%
3/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
Gastrointestinal disorders
nausea
|
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
General disorders
dizziness
|
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
General disorders
dry mouth
|
25.0%
2/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
22.2%
2/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
General disorders
insomnia
|
12.5%
1/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
33.3%
3/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
|
General disorders
vomiting
|
12.5%
1/8 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
11.1%
1/9 • Adverse effects identified by standard querying for new onset or worsened symptoms on a standard checklist administered bi-weekly.
Side Effect Check (SEC) List was used
|
Additional Information
Dr. Robert W. Buchanan
Maryland Psychiatric Research Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place